NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Epistemonikos ID: a1bf180bd522b87a7c932875e0082ff3078f62bc
First added on: May 09, 2024